GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (CHIX:SDZz) » Definitions » Buyback Yield %

Sandoz Group AG (CHIX:SDZZ) Buyback Yield % : 0.07 (As of Dec. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Sandoz Group AG's current buyback yield was 0.07%.


Sandoz Group AG Buyback Yield % Historical Data

The historical data trend for Sandoz Group AG's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Buyback Yield % Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Buyback Yield %
- -

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Buyback Yield % - - - 0.15

Competitive Comparison of Sandoz Group AG's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Buyback Yield % falls into.



Sandoz Group AG Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Sandoz Group AG's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 11651.0759
=0.00%

Sandoz Group AG's annualized Buyback Yield for the quarter that ended in Jun. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-10.726 + 0) * 2 / 14331.03185
=0.15%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Jun. 2024) data.


Sandoz Group AG Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG Business Description

Comparable Companies
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines